Limits...
Novel treatment options for nonmelanoma skin cancer: focus on electronic brachytherapy.

Kasper ME, Chaudhary AA - Med Devices (Auckl) (2015)

Bottom Line: Radiotherapy has a long history in the treatment of NMSC.Shortly after the discovery of X-rays and (226)Radium, physicians cured patients with NMSC using these new treatments.Both X-ray therapy and brachytherapy have evolved over the years, ultimately delivering higher cure rates and lower toxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Lynn Cancer Institute at Boca Raton Regional Hospital, Boca Raton, USA ; Charles E. Schmidt College of Medicine, Florida Atlantic University, FL, USA.

ABSTRACT
Nonmelanoma skin cancer (NMSC) is an increasing health care issue in the United States, significantly affecting quality of life and impacting health care costs. Radiotherapy has a long history in the treatment of NMSC. Shortly after the discovery of X-rays and (226)Radium, physicians cured patients with NMSC using these new treatments. Both X-ray therapy and brachytherapy have evolved over the years, ultimately delivering higher cure rates and lower toxicity. Electronic brachytherapy for NMSC is based on the technical and clinical data obtained from radionuclide skin surface brachytherapy and the small skin surface applicators developed over the past 25 years. The purpose of this review is to introduce electronic brachytherapy in the context of the history, data, and utilization of traditional radiotherapy and brachytherapy.

No MeSH data available.


Related in: MedlinePlus

The Xoft® Axxent® electronic brachytherapy system (iCAD, Inc.) external trolley.Note: Reproduced from XoftInc.com [homepage on the Internet]. Axxess with Axxent: Innovative Technology for the Practice of Radiation Oncology. California: Xoft, inc.; 2008. Available from: http://www.xoftinc.com/treatingebx.html.15
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664532&req=5

f1-mder-8-493: The Xoft® Axxent® electronic brachytherapy system (iCAD, Inc.) external trolley.Note: Reproduced from XoftInc.com [homepage on the Internet]. Axxess with Axxent: Innovative Technology for the Practice of Radiation Oncology. California: Xoft, inc.; 2008. Available from: http://www.xoftinc.com/treatingebx.html.15

Mentions: The currently available eBT devices are the Xoft® Axxent®, Zeiss® INTRABEAM®, and Elekta® Esteya®. The Xoft Axxent electronic brachytherapy system® (iCAD Inc., Nashua, NH, USA) incorporates a 23 mm proprietary X-ray source with a multilumen catheter and is used in the treatment of skin cancer, early stage breast cancer, and gynecological malignancies (Figure 1).15,16 It consists of a mobile controller that provides power and cooling to the source, a HDR X-ray source, and applicator sets. Superficial, NMSCs are treated using United States Food and Drug Administration (FDA) approved, lightweight surface applicator placed directly over the target lesion. Surface applicators measure 10 mm, 20 mm, 35 mm, and 50 mm in diameter with corresponding end caps (Figure 2).15 Similar to radionuclide HDR brachytherapy, the miniature X-ray source can be stepped along the catheter to deliver the optimal treatment. Low-energy photons are generated in the source by accelerating electrons that then strike a tungsten target. The source to skin distance (SSD) is 25 mm. The X-ray source tube diameter is 2.25 mm, and the X-ray source has a power of 50 W. The controller has a beam current of 300 μA and a selectable high-voltage output with maximum photon energy of 50 kV. Typical treatment time is 4–10 minutes, and the maximum number of treatments per X-ray source is 250–500 minutes of treatment.15–17


Novel treatment options for nonmelanoma skin cancer: focus on electronic brachytherapy.

Kasper ME, Chaudhary AA - Med Devices (Auckl) (2015)

The Xoft® Axxent® electronic brachytherapy system (iCAD, Inc.) external trolley.Note: Reproduced from XoftInc.com [homepage on the Internet]. Axxess with Axxent: Innovative Technology for the Practice of Radiation Oncology. California: Xoft, inc.; 2008. Available from: http://www.xoftinc.com/treatingebx.html.15
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664532&req=5

f1-mder-8-493: The Xoft® Axxent® electronic brachytherapy system (iCAD, Inc.) external trolley.Note: Reproduced from XoftInc.com [homepage on the Internet]. Axxess with Axxent: Innovative Technology for the Practice of Radiation Oncology. California: Xoft, inc.; 2008. Available from: http://www.xoftinc.com/treatingebx.html.15
Mentions: The currently available eBT devices are the Xoft® Axxent®, Zeiss® INTRABEAM®, and Elekta® Esteya®. The Xoft Axxent electronic brachytherapy system® (iCAD Inc., Nashua, NH, USA) incorporates a 23 mm proprietary X-ray source with a multilumen catheter and is used in the treatment of skin cancer, early stage breast cancer, and gynecological malignancies (Figure 1).15,16 It consists of a mobile controller that provides power and cooling to the source, a HDR X-ray source, and applicator sets. Superficial, NMSCs are treated using United States Food and Drug Administration (FDA) approved, lightweight surface applicator placed directly over the target lesion. Surface applicators measure 10 mm, 20 mm, 35 mm, and 50 mm in diameter with corresponding end caps (Figure 2).15 Similar to radionuclide HDR brachytherapy, the miniature X-ray source can be stepped along the catheter to deliver the optimal treatment. Low-energy photons are generated in the source by accelerating electrons that then strike a tungsten target. The source to skin distance (SSD) is 25 mm. The X-ray source tube diameter is 2.25 mm, and the X-ray source has a power of 50 W. The controller has a beam current of 300 μA and a selectable high-voltage output with maximum photon energy of 50 kV. Typical treatment time is 4–10 minutes, and the maximum number of treatments per X-ray source is 250–500 minutes of treatment.15–17

Bottom Line: Radiotherapy has a long history in the treatment of NMSC.Shortly after the discovery of X-rays and (226)Radium, physicians cured patients with NMSC using these new treatments.Both X-ray therapy and brachytherapy have evolved over the years, ultimately delivering higher cure rates and lower toxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Lynn Cancer Institute at Boca Raton Regional Hospital, Boca Raton, USA ; Charles E. Schmidt College of Medicine, Florida Atlantic University, FL, USA.

ABSTRACT
Nonmelanoma skin cancer (NMSC) is an increasing health care issue in the United States, significantly affecting quality of life and impacting health care costs. Radiotherapy has a long history in the treatment of NMSC. Shortly after the discovery of X-rays and (226)Radium, physicians cured patients with NMSC using these new treatments. Both X-ray therapy and brachytherapy have evolved over the years, ultimately delivering higher cure rates and lower toxicity. Electronic brachytherapy for NMSC is based on the technical and clinical data obtained from radionuclide skin surface brachytherapy and the small skin surface applicators developed over the past 25 years. The purpose of this review is to introduce electronic brachytherapy in the context of the history, data, and utilization of traditional radiotherapy and brachytherapy.

No MeSH data available.


Related in: MedlinePlus